Simge Senyuz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Simge Senyuz has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Attila Gursoy
Koc University
5 shared publications - Ozlem Keskin
Koc University
3 shared publications - Ahenk Zeynep Sayin
Department of Chemical and Biological Engineering, Koç University, Istanbul 34450, Turkey
2 shared publications - Fatma Cankara
Graduate School of Sciences and Engineering, Koç University, Istanbul 34450, Turkey
2 shared publications - Melisa Ece Zeylan
Computational Sciences and Engineering, Graduate School of Science and Engineering, Koç University
2 shared publications Ozlem Keskin
Department of Chemical and Biological Engineering, Koc Univeristy, Rumelifeneri Yolu, Istanbul, Turkey
2 shared publications
Latest Publications
- Open Access
- 21 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
Tumor-derived RHOA mutants interact with effectors in the GDP-bound state
RHOA mutations are found at diverse residues in various cancer types, implying mutation- and cell-specific mechanisms of tumorigenesis. Here, we focus on the underlying mechanisms of two gain-of-function RHOA mutations, A161P and A161V, identified in adult T-cell leukemia/lymphoma. We find that RHOAA161P and RHOAA161V are both fast-cycling mutants with increased guanine nucleotide dissociation/association rates compared with RHOAWT and show reduced GTP-hydrolysis activity. Crystal structures reveal an altered nucleotide association in RHOAA161P and an open nucleotide pocket in RHOAA161V. Both mutations perturb the dynamic properties of RHOA switch regions and shift the conformational landscape important for RHOA activity, as shown by 31P NMR and molecular dynamics simulations. Interestingly, RHOAA161P and RHOAA161V can interact with effectors in the GDP-bound state. 1H-15N HSQC NMR spectra support the existence of an active population in RHOAA161V-GDP. The distinct interaction mechanisms resulting from the mutations likely favor an RHOAWT-like “ON” conformation, endowing GDP-bound state effector binding activity.
- 21 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
Open AccessTumor-derived RHOA mutants interact with effectors in the GDP-bound state
RHOA mutations are found at diverse residues in various cancer types, implying mutation- and cell-specific mechanisms of tumorigenesis. Here, we focus on the underlying mechanisms of two gain-of-function RHOA mutations, A161P and A161V, identified in adult T-cell leukemia/lymphoma. We find that RHOAA161P and RHOAA161V are both fast-cycling mutants with increased guanine nucleotide dissociation/association rates compared with RHOAWT and show reduced GTP-hydrolysis activity. Crystal structures reveal an altered nucleotide association in RHOAA161P and an open nucleotide pocket in RHOAA161V. Both mutations perturb the dynamic properties of RHOA switch regions and shift the conformational landscape important for RHOA activity, as shown by 31P NMR and molecular dynamics simulations. Interestingly, RHOAA161P and RHOAA161V can interact with effectors in the GDP-bound state. 1H-15N HSQC NMR spectra support the existence of an active population in RHOAA161V-GDP. The distinct interaction mechanisms resulting from the mutations likely favor an RHOAWT-like “ON” conformation, endowing GDP-bound state effector binding activity.
- Open Access
- 22 June 2024
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 64 (13) , 5041-5051
DiPPI: A Curated Data Set for Drug-like Molecules in Protein–Protein Interfaces
Proteins interact through their interfaces, and dysfunction of protein-protein interactions (PPIs) has been associated with various diseases. Therefore, investigating the properties of the drug-modulated PPIs and interface-targeting drugs is critical. Here, we present a curated large data set for drug-like molecules in protein interfaces. We further introduce DiPPI (Drugs in Protein-Protein Interfaces), a two-module web site to facilitate the search for such molecules and their properties by exploiting our data set in drug repurposing studies. In the interface module of the web site, we present several properties, of interfaces, such as amino acid properties, hotspots, evolutionary conservation of drug-binding amino acids, and post-translational modifications of these residues. On the drug-like molecule side, we list drug-like small molecules and FDA-approved drugs from various databases and highlight those that bind to the interfaces. We further clustered the drugs based on their molecular fingerprints to confine the search for an alternative drug to a smaller space. Drug properties, including Lipinski's rules and various molecular descriptors, are also calculated and made available on the web site to guide the selection of drug molecules. Our data set contains 534,203 interfaces for 98,632 protein structures, of which 55,135 are detected to bind to a drug-like molecule. 2214 drug-like molecules are deposited on our web site, among which 335 are FDA-approved. DiPPI provides users with an easy-to-follow scheme for drug repurposing studies through its well-curated and clustered interface and drug data and is freely available at http://interactome.ku.edu.tr:8501.
- 22 June 2024
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 64 (13) , 5041-5051
Open AccessDiPPI: A Curated Data Set for Drug-like Molecules in Protein–Protein Interfaces
Proteins interact through their interfaces, and dysfunction of protein-protein interactions (PPIs) has been associated with various diseases. Therefore, investigating the properties of the drug-modulated PPIs and interface-targeting drugs is critical. Here, we present a curated large data set for drug-like molecules in protein interfaces. We further introduce DiPPI (Drugs in Protein-Protein Interfaces), a two-module web site to facilitate the search for such molecules and their properties by exploiting our data set in drug repurposing studies. In the interface module of the web site, we present several properties, of interfaces, such as amino acid properties, hotspots, evolutionary conservation of drug-binding amino acids, and post-translational modifications of these residues. On the drug-like molecule side, we list drug-like small molecules and FDA-approved drugs from various databases and highlight those that bind to the interfaces. We further clustered the drugs based on their molecular fingerprints to confine the search for an alternative drug to a smaller space. Drug properties, including Lipinski's rules and various molecular descriptors, are also calculated and made available on the web site to guide the selection of drug molecules. Our data set contains 534,203 interfaces for 98,632 protein structures, of which 55,135 are detected to bind to a drug-like molecule. 2214 drug-like molecules are deposited on our web site, among which 335 are FDA-approved. DiPPI provides users with an easy-to-follow scheme for drug repurposing studies through its well-curated and clustered interface and drug data and is freely available at http://interactome.ku.edu.tr:8501.
- Open Access
Understanding Molecular Links of Vascular Cognitive Impairment: Selective Interaction between Mutant APP, TP53, and MAPKs
Vascular cognitive impairment (VCI) is an understudied cerebrovascular disease. As it can result in a significant amount of functional and cognitive disabilities, it is vital to reveal proteins related to it. Our study focuses on revealing proteins related to this complex disease by deciphering the crosstalk between cardiovascular and cognitive diseases. We build protein-protein interaction networks related to cardiovascular and cognitive diseases. After merging these networks, we analyze the network to extract the hub proteins and their interactors. We found the clusters on this network and built the structural protein-protein interaction network of the most connected cluster on the network. We analyzed the interactions of this network with molecular modeling via PRISM. PRISM predicted several interactions that can be novel in the context of VCI-related interactions. Two mutant forms of APP (V715M and L723P), previously not connected to VCI, were discovered to interact with other proteins. Our findings demonstrate that two mutant forms of APP interact differently with TP53 and MAPK’s. Furthermore, TP53, AKT1, PARP1, and FGFR1 interact with MAPKs through their mutant conformations. We hypothesize that these interactions might be crucial for VCI. We suggest that these interactions and proteins can act as early VCI markers or as possible therapeutic targets.
Open AccessUnderstanding Molecular Links of Vascular Cognitive Impairment: Selective Interaction between Mutant APP, TP53, and MAPKs
Vascular cognitive impairment (VCI) is an understudied cerebrovascular disease. As it can result in a significant amount of functional and cognitive disabilities, it is vital to reveal proteins related to it. Our study focuses on revealing proteins related to this complex disease by deciphering the crosstalk between cardiovascular and cognitive diseases. We build protein-protein interaction networks related to cardiovascular and cognitive diseases. After merging these networks, we analyze the network to extract the hub proteins and their interactors. We found the clusters on this network and built the structural protein-protein interaction network of the most connected cluster on the network. We analyzed the interactions of this network with molecular modeling via PRISM. PRISM predicted several interactions that can be novel in the context of VCI-related interactions. Two mutant forms of APP (V715M and L723P), previously not connected to VCI, were discovered to interact with other proteins. Our findings demonstrate that two mutant forms of APP interact differently with TP53 and MAPK’s. Furthermore, TP53, AKT1, PARP1, and FGFR1 interact with MAPKs through their mutant conformations. We hypothesize that these interactions might be crucial for VCI. We suggest that these interactions and proteins can act as early VCI markers or as possible therapeutic targets.
- Open Access
DiPPI: A curated dataset for drug-like molecules in protein-protein interfaces
Proteins interact through their interfaces, and dysfunction of protein-protein interactions (PPIs) has been associated with various diseases. Therefore, investigating the properties of the drug-modulated PPIs and interface-targeting drugs is critical. Here, we present a curated large dataset for drug-like molecules in protein interfaces. We further present DiPPI (Drugs in Protein-Protein Interfaces), a two-module website to facilitate the search for such molecules and their properties by exploiting our dataset in drug repurposing studies. In the interface module of the website, we extracted several properties of interfaces, such as amino acid properties, hotspots, evolutionary conservation of drug-binding amino acids, and post-translational modifications of these residues. On the drug-like molecule side, we curated a list of drug-like small molecules and FDA-approved drugs from various databases and extracted those that bind to the interfaces. We further clustered the drugs based on their molecular fingerprints to confine the search for an alternative drug to a smaller space. Drug properties, including Lipinski’s rules and various molecular descriptors, are also calculated and made available on the website to guide the selection of drug molecules. Our dataset contains 534,203 interfaces for 98,632 proteins, of which 55,135 are detected to bind to a drug-like molecule. 2,214 drug-like molecules are deposited on our website, among which 335 are FDA-approved. DiPPI provides users with an easy-to-follow scheme for drug repurposing studies through its well-curated and clustered interface and drug data; and is freely available at http://interactome.ku.edu.tr:8501 .
Open AccessDiPPI: A curated dataset for drug-like molecules in protein-protein interfaces
Proteins interact through their interfaces, and dysfunction of protein-protein interactions (PPIs) has been associated with various diseases. Therefore, investigating the properties of the drug-modulated PPIs and interface-targeting drugs is critical. Here, we present a curated large dataset for drug-like molecules in protein interfaces. We further present DiPPI (Drugs in Protein-Protein Interfaces), a two-module website to facilitate the search for such molecules and their properties by exploiting our dataset in drug repurposing studies. In the interface module of the website, we extracted several properties of interfaces, such as amino acid properties, hotspots, evolutionary conservation of drug-binding amino acids, and post-translational modifications of these residues. On the drug-like molecule side, we curated a list of drug-like small molecules and FDA-approved drugs from various databases and extracted those that bind to the interfaces. We further clustered the drugs based on their molecular fingerprints to confine the search for an alternative drug to a smaller space. Drug properties, including Lipinski’s rules and various molecular descriptors, are also calculated and made available on the website to guide the selection of drug molecules. Our dataset contains 534,203 interfaces for 98,632 proteins, of which 55,135 are detected to bind to a drug-like molecule. 2,214 drug-like molecules are deposited on our website, among which 335 are FDA-approved. DiPPI provides users with an easy-to-follow scheme for drug repurposing studies through its well-curated and clustered interface and drug data; and is freely available at http://interactome.ku.edu.tr:8501 .
- Open Access
Revealing Shared Proteins and Pathways in Cardiovascular and Cognitive Diseases Using Protein Interaction Network Analysis
One of the primary goals of systems medicine is detecting putative proteins and pathways involved in disease progression and pathological phenotypes. Vascular Cognitive Impairment (VCI) is a heterogeneous condition manifesting as cognitive impairment resulting from vascular factors. The precise mechanisms underlying this relationship remain unclear, which poses challenges for experimental research. Here, we applied computational approaches like systems biology to unveil and select relevant proteins and pathways related to VCI by studying the crosstalk between cardiovascular and cognitive diseases. In addition, we specifically included signals related to oxidative stress, a common etiologic factor tightly linked to aging, a major determinant of VCI. Our results show that pathways associated with oxidative stress are quite relevant, as most of the prioritized vascular-cognitive genes/proteins were enriched in these pathways. Our analysis provided a short list of proteins that could be contributing to VCI: DOLK, TSC1, ATP1A1, MAPK14, YWHAZ, CREB3, HSPB1, PRDX6, and LMNA. Moreover, our experimental results suggest a high implication of glycative stress, generating oxidative processes and post-translational protein modifications through advanced glycation end-products (AGEs). We propose that these products interact with their specific receptors (RAGE) and Notch signaling to contribute to the etiology of VCI.
Open AccessRevealing Shared Proteins and Pathways in Cardiovascular and Cognitive Diseases Using Protein Interaction Network Analysis
One of the primary goals of systems medicine is detecting putative proteins and pathways involved in disease progression and pathological phenotypes. Vascular Cognitive Impairment (VCI) is a heterogeneous condition manifesting as cognitive impairment resulting from vascular factors. The precise mechanisms underlying this relationship remain unclear, which poses challenges for experimental research. Here, we applied computational approaches like systems biology to unveil and select relevant proteins and pathways related to VCI by studying the crosstalk between cardiovascular and cognitive diseases. In addition, we specifically included signals related to oxidative stress, a common etiologic factor tightly linked to aging, a major determinant of VCI. Our results show that pathways associated with oxidative stress are quite relevant, as most of the prioritized vascular-cognitive genes/proteins were enriched in these pathways. Our analysis provided a short list of proteins that could be contributing to VCI: DOLK, TSC1, ATP1A1, MAPK14, YWHAZ, CREB3, HSPB1, PRDX6, and LMNA. Moreover, our experimental results suggest a high implication of glycative stress, generating oxidative processes and post-translational protein modifications through advanced glycation end-products (AGEs). We propose that these products interact with their specific receptors (RAGE) and Notch signaling to contribute to the etiology of VCI.